TherapeutAix NASH review article is now available online!

At the end of last year, TherapeutAix published an article titled ‘The future R&D landscape in non-alcoholic steatohepatitis’ in Drug Discovery Today. The review aims to give drug discovery teams guidance on navigating the maze of information currently available on NASH and to provide pointers on areas to consider in early research projects.

The final version of the article has now been made available online by Elsevier. The full article, including full bibliographic details, is available for you for a limited period of time.

Click the link here to get free access to the article, which you can read and download before April 16th 2019.

The highlights of the article:

  • There is an unmet need for new therapies to treat NASH.
  • New therapies will have different modes of action, aligned to the stage of disease.
  • They must have additive benefit, in combination with emerging standards of care.
  • New biomarkers and pre-clinical models will facilitate drug research and development.
  • The new therapeutic approaches could permit individualised patient treatment. 

If you think we could help you optimise your drug discovery programme in fibrosis, NASH or other areas, or if you have a molecule with promise that you need our help with, please email us at or contact us here. 

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.